ARTICLE | Clinical News
Dermira data could bolster bid as Dupixent alternative
October 19, 2019 1:03 AM UTC
Updated on Oct 22, 2019 at 12:07 AM UTC
Dermira added $80 million to its market cap Friday on detailed Phase IIb data that lend additional support to the idea that its atopic dermatitis therapy could compete with Dupixent on dosing.
Dermira Inc. (NASDAQ:DERM) reported top-line data in March showing that all three doses of lebrikizumab met the study’s primary endpoint of reducing disease severity, measured on the Eczema Area and Severity Index (EASI), at week 16 vs. placebo in adults with moderate-to-severe atopic dermatitis (see “Dermira Jumps on Phase IIb Atopic Dermatitis Readout”)...
BCIQ Target Profiles